Effect on intragastric pH of a PPI with a prolonged plasma half-life: Comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers

American Journal of Gastroenterology

Volumn 100, Issue 9, 2005, Pages 1949-1956

  Hunt, Richard H ^a   Armstrong, David ^a   James, Cindy ^a   Chowdhury, Sadat K ^a   Yuan, Yuhong ^a   Fiorentini, Paola ^b   Taccoen, Alain ^b   Cohen, Patrick ^b  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^b Laboratoires Negma   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENATOPRAZOLE; ESOMEPRAZOLE; PROTON PUMP INHIBITOR; ANTIULCER AGENT; DRUG DERIVATIVE; IMIDAZOLE DERIVATIVE; OMEPRAZOLE; PROTON PUMP; PYRIDINE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HEADACHE; HELICOBACTER PYLORI; HUMAN; MALE; NIGHT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STOMACH PH; TREATMENT WITHDRAWAL; VOLUNTEER; ADOLESCENT; BLOOD; COMPARATIVE STUDY; DRUG ANTAGONISM; HALF LIFE TIME; STOMACH;

ADOLESCENT; ADULT; ANTI-ULCER AGENTS; CROSS-OVER STUDIES; GASTRIC ACIDITY DETERMINATION; HALF-LIFE; HUMANS; IMIDAZOLES; MALE; OMEPRAZOLE; PROTON PUMPS; PYRIDINES; STOMACH;

EID: 27744510967     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.41956.x     Document Type: Article

References (37)

1. Jones DB Howden CW Burget DW, et al. Acid suppression in duodenal ulcer: A meta-analysis to define optimal dosing with antisecretory drugs. Gut 1987 28 : 1120 27.
2. Howden CW Jones DB Peace KE, et al. The treatment of gastric ulcer with antisecretory drugs. Relationship of pharmacological effect to healing rates. Dig Dis Sci 1988 33 : 619 24.
3. Burget DW Chiverton SG Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990 99 : 345 51.
4. Bell NJ Hunt RH. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 1992 33 : 118 24.
5. Hunt RH Cederberg C Dent J, et al. Optimizing acid suppression for treatment of acid-related diseases. Dig Dis Sci 1995 40 ( 2 suppl 24S 49S.
6. Lind T Rydberg L Kyleback A, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000 14 : 861 7.
7. Miner P Jr. Katz PO Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: A five-way crossover study. Am J Gastroenterol 2003 98 : 2616 20.
8. Lundell L Miettinen P Myrvold HE, et al. Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg 2001 192 : 172 9.
9. Shin JM Cho YM Sachs G. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors. J Am Chem Soc 2004 126 : 7800 811.
10. Sachs G Shin JM Briving C, et al. The pharmacology of the gastric acid pump: The H+, K+ ATPase. Annu Rev Pharmacol Toxicol 1995 35 : 277 305.
11. Domagala F Ficheux H. Pharmacokinetics of tenatoprazole, a novel proton pump inhibitor, in healthy male Caucasian volunteers. Gastroenterology 2003 124 : S1608 (abstract 102823).
12. Galmiche JP Bruley Des Varannes S Ducrotte P, et al. Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: Effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment Pharmacol Ther 2004 19 : 655 62.
13. Tutuian R Katz PO Castell DO. Nocturnal acid breakthrough: pH, drugs and bugs. Eur J Gastroenterol Hepatol 2004 16 : 441 3.
14. Gardner JD Rodriguez-Stanley S Robinson M. Integrated acidity and the pathophysiology of GERD. Am J Gastroenterol 2001 96 : 1363 70.
15. Ouatu-Lascar R Fitzgerald RC Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999 117 : 327 35.
16. Srinivasan R Katz PO Ramakrishnan A, et al. Maximal acid reflux control for Barrett's oesophagus: Feasible and effective. Aliment Pharmacol Ther 2001 15 : 519 24.
17. Castell DO. Does acid suppression alter progression in Barrett's esophagus? Am J Gastroenterol 2003 98 : 213 14.
18. El-Serag HB Aguirre TV Davis S, et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004 99 : 1877 83.
19. Hillman LC Chiragakis L Shadbolt B, et al. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 2004 180 : 387 91.
20. Armstrong D Talley NJ Lauritsen K, et al. The role of acid suppression in patients with endoscopy-negative reflux disease: The effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther 2004 20 : 413 21.
21. Salas M Ward A Caro J. Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials. BMC Gastroenterol 2002 2 : 17.
22. Yeomans ND Tulassay Z Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998 338 : 719 26.
23. Agrawal NM Campbell DR Safdi MA, et al. For the NSAID-Associated Gastric Ulcer Study Group. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers. Results of a Double-blind, Randomized, Multicenter Study. Arch Intern Med 2000 160 : 1455 61.
24. Yeomans N Scheiman JM Hawkey CJ, et al. An evidence-based analysis of esomeprazole therapy versus placebo for the prevention of gastric or duodenal ulcers in at-risk continuous NSAID users. Gastroenterology 2004 126 ( suppl 2 A 604.
25. Hawkey CJ Karrasch JA Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998 338 : 727 34.
26. Figura N Crabtree JE Dattilo M. In vitro activity of lansoprazole against Helicobacter pylori. J Antimicrob Chemother 1997 39 : 585 90.
27. Gatta L Perna F Figura N, et al. Antimicrobial activity of esomeprazole versus omeprazole against Helicobacter pylori. J Antimicrob Chemother 2003 51 : 439 42.
28. Debets-Ossenkopp YJ Namavar F MacLaren DM. Effect of an acidic environment on the susceptibility of Helicobacter pylori to trospectomycin and other antimicrobial agents. Eur J Clin Microbiol Infect Dis 1995 14 : 353 5.
29. Scott D Weeks D Melchers K, et al. The life and death of Helicobacter pylori. Gut 1998 43 ( suppl 1 S56 60.
30. Goddard AF Jessa MJ Barrett DA. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 1996 111 : 358 67.
31. Ushiama H Echizen H Nachi S, et al. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol. Clin Pharmacol Ther 2002 72 : 33 43.
32. Furuta T Ohashi K Kobayashi K, et al. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clin Pharmacol Ther 1999 66 : 265 74.
33. Robinson M Horn J. Clinical pharmacology of proton pump inhibitors, what the practising physician needs to know. Drugs 2003 63 : 2739 54.
34. Zed PJ Loewen PS Slavik RS, et al. Meta-analysis of proton pump inhibitors in treatment of bleeding peptic ulcers. Ann Pharmacother 2001 35 : 1528 34.
35. Barkun A Sabbah S Enns R, et al. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): Endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol 2004 99 : 1238 46.
36. Armstrong D Bair D James C, et al. Oral esomeprazole vs. intravenous pantoprazole: A comparison of the effect on intragastric pH in healthy subjects. Aliment Pharmacol Ther 2003 18 : 705 11.
37. Furuta T Shirai N Sugimoto M, et al. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 2004 5 : 181 202.